Cardinal Health’s (NYSE:CAH) Health Specialty Division, a division responsible for the research and development in the medicine field specialization, has announced that it will present a series of research paper studies later this week on the economic health outcome that aims to reiterate the importance of reviewing real world treatment patterns while developing value-based reimbursement strategies.
Dr. Bruce Feinberg, who serves as the vice president and CMO of Cardinal Health Specialty Solutions, has stated that for professional doctors, physicians, and pharmaceutical companies alike had been aware that statistical results conducted through clinical trials do not entirely reflect on how cancer treatments are conducted in real time alone, for which insurance payers are watching the disparity closely and are now adjusting reimbursement strategies in response to it.
According to Mr. Feinberg, the new research, which will be released ahead of the 2015 American Society of Clinical Oncology Annual Meeting in Chicago by next month, will confirm that ‘Health Economic Outcomes’ data can play a better role in helping insurance payers to get a better understanding of treatments in practical scenarios, in turn, helping to have a better sense on developing strategies for the value-based reimbursement
Since the last year upto now, Cardinal Health Specialty Solutions has released a voluminous amount of studies featuring real world treatment patterns for diseases, such as leukemia care, and what economic impact that has on patient care.
Meanwhile, FTC has announced its less than $27 million settlement with Cardinal Health Inc., after it charged the healthcare services company of illegally monopolizing around 25 local markets in the country for the sale/distribution of low energy radiopharmaceuticals, that has forced hospitals to pay inflated prices for the purchase of those drugs. The $27 million is considered as the largest disgorgement in the FTC history and will be distributed amongst injured customers based on the validity of their claims.
The final order provides an injunction to the purchase and sale of the radiopharmaceutical drugs, and the ruling requires Cardinal Health to constitute an antitrust compliance program for its Nuclear Pharmacy division. Lawyers say this settlement serves as a reminder that antitrust disgorgement penalties on healthcare services are gaining traction and the conduct of any matter short of the explicit agreement runs foul to antitrust laws.
Cardinal Health stock price ended the day trading at $88.16, a gain of more than 0.60% the previous day, despite the confirmation of the ruling that has taken a hit on the company’s earnings last month.
No comments:
Post a Comment